67 results about "L-Pyroglutamic Acid" patented technology

The invention belongs to the field of medicines, and discloses application of pyroglutamic acid in preparation of products for inhibiting fat deposition. The invention has the following advantages: 1, obesity induced by high fat diet is prevented; 2, pyroglutamic acid is a natural amino acid derivative, widely exists in animal and plant bodies, and has good biological safety; meanwhile, the invention further discloses a product for inhibiting fat deposition.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention provides application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract, and belongs to the technical field of medicines. The invention discloses application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract. Results of the invention show that the D-pyroglutamic acid can effectively inhibit aggregation of crystalline lens proteins. In addition, the D-pyroglutamic acid drug is low in cytotoxicity, directly acts on crystalline epithelial cells and can effectively inhibit damage to the crystalline epithelial cells. Therefore, the medical application of the D-pyroglutamic acid is expanded, and meanwhile, a new diagnosis and treatment strategy is provided for attack and prevention of cataract.

To provide a technique for reducing undesirable sourness generated during long-term storage in a food composition containing acetic acid.SOLUTION: Provided is a food composition that fulfills the following requirements (i) and (ii): (i) the content of acetic acid is 2 mass% or more; (ii) the proportion of the content (mass ppm) of pyroglutamic acid to the content (mass%) of acetic acid is 70 or less.SELECTED DRAWING: None

The application discloses derivatives of pyroglutamic acid-tetrapeptide-7 and application thereof. The derivatives of pyroglutamic acid-tetrapeptide-7 or pharmaceutically acceptable salts thereof have the following structure: the substituent R is selected from the group consisting of. The derivatives of pyroglutamic acid-tetrapeptide-7 have excellent effects of anti-inflammation, promoting synthesis of collagen and / or elastin, reducing wrinkle area or wrinkle degree, and have a smaller effective concentration compared with tetrapeptide-7, and can be applied to medicines, cosmetics or skin care products as main active ingredients.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to clofazimine-organic acid co-crystals, a preparation method and application thereof. The clofazimine-organic acid co-crystal is one of clofazimine-ferulic acid monohydrate co-crystal, clofazimine-ferulic acid co-crystal, clofazimine-glutaric acid co-crystal, clofazimine-glycolic acid co-crystal (CFZ-GA 1:1), clofazimine-glycolic acid co-crystal (CFZ-GA 1:1.5), clofazimine-salicylic acid co-crystal, clofazimine-L-aspartic acid co-crystal, clofazimine-L-pyroglutamic acid co-crystal, clofazimine-gallic acid co-crystal, clofazimine-succinic acid co-crystal, clofazimine-tartaric acid co-crystal and clofazimine-DL-mandelic acid co-crystal. The clofazimine-organic acid co-crystal provided by the application significantly improves the solubility and fluidity of clofazimine, thereby improving the bioavailability of clofazimine, and has a broad medicinal prospect.

The invention belongs to the technical field of medicines, and discloses an arbutin amino acid derivative as well as a preparation method and application thereof. According to the invention, a microbial conversion technology is utilized, the arbutin is taken as a substrate, pyroglutamic acid is introduced to the 28 site of the arbutin in a regioselective manner, and the arbutin-28beta-pyroglutamate with a novel structure is obtained. An in-vitro anti-tumor cell test proves that the compound has remarkable anti-tumor activity and can be used as an active component of an anti-tumor drug. A mouse in-vivo experiment proves that the compound has a remarkable anti-osteoporosis effect, can be used as an active ingredient of an anti-osteoporosis medicine, and has wide application.

The invention belongs to the technical field of compound preparation, and particularly provides a preparation method of L-glutamic acid-1-tert-butyl ester, which comprises the following steps: step S1, carrying out imidization reaction on an L-glutamic acid-5-methyl ester compound and benzophenone imine to generate N-dibenzylidene-L-glutamic acid-5-methyl ester; step S2, enabling the N-dibenzylidene-L-glutamic acid-5-methyl ester and tertiary butyl-2, 2, 2-trichloroacetic acid imine ester to be subjected to a tert-butyl esterification reaction, so as to generate N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester, and enabling the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester to be subjected to a tert-butyl esterification reaction; and S3, carrying out hydrolysis reaction on the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester to remove a methyl ester group, and removing a protecting group on an amino group, so as to generate the L-glutamic acid-1-tert-butyl ester. The preparation method disclosed by the embodiment of the invention is used for preparing the L-glutamic acid-5-methyl ester-1-tert-butyl ester from the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester. According to the application, the tertiary butyl-2, 2, 2-trichloroacetic acid imine ester is used for carrying out the tert-butyl esterification reaction, so that the yield is high, the reaction condition is mild, the post-treatment is simple, the control on the generation of glutamic acid, pyroglutamic acid and pyroglutamic acid tert-butyl ester is facilitated, and the impurities are few.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a metabolic marker in preparation of a product for diagnosing abdominal aortic aneurysm. The metabolic marker comprises one or more than two of 5-delta-hydroxybutyl hydantoin, I-alpha-amino acid, PGF2 alpha, D-pyroglutamic acid, nicotine glucuronide, cysteine glutathione disulfide or Trp-P-1. Experiments prove that the metabolic marker has the advantages that the metabolic marker can be applied to the field of biomarkers, and the metabolic marker can be applied to the field of biomarkers; the seven metabolites are independently or jointly used as metabolic markers for diagnosing the abdominal aortic aneurysm and have good specificity and sensitivity.

LSD derivative compounds and polymorphs thereof, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula I' selected from,,,, or combination thereof, wherein the acid is selected from formic acid, malic acid (D and L), pyroglutamic acid (D and L), citric acid, phosphoric acid, aspartic acid (D and L), methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, sulfuric acid, glutamic acid (D and L), ascorbic acid (D and L), isoascorbic acid (D and L), hydrochloric acid, hydrobromic acid, ethane sulfonic acid, tartaric acid (D and L), or meso-tartaric acid.

The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

To provide a technology for suppressing unpleasant sourness that occurs in a food composition containing acetic acid when stored for a long period of time. [Solution] A food composition that satisfies the following requirements (i) and (ii). (i) The acetic acid content is 3.0% by mass or more. (ii) The ratio of the pyroglutamic acid content (ppm by mass) to the acetic acid content (% by mass) is 70 or less.

To provide a new alcoholic beverage having various flavor attributes favorable for use as an alcoholic beverage.SOLUTION: An alcoholic beverage containing 10.0 to 180.0 mg / L of pyroglutamic acid, 12.0 to 55.0 mg / L of ethyl acetate, and a total of 130.0 to 900.0 μg / L of ethyl hexanoate and ethyl octanoate.SELECTED DRAWING: None

To meet a need for a fermented beverage that is made by using hops and offers a favorable, characteristic flavor typical of a fermented beverage while achieving a reduction in unsuitable grain odor.SOLUTION: Provided is a fermented beverage that is made by using hops as a raw material, has a pyroglutamic acid content of 95.0 mg / L or less, and satisfies formula (1): A / B≤30.0, wherein in formula (1), A represents the pyroglutamic acid content (unit: mg / L) and B represents the free amino nitrogen content (unit: mg / 100 mL).SELECTED DRAWING: None

An antibody or antigen-binding fragment thereof that binds to A [beta] pE3, i.e., to the N-terminal truncated and pyroglutamic acid modified form of amyloid [beta] (A [beta]), and therapeutic and diagnostic uses thereof are disclosed.

The processed food product has a xanthine / pyroglutamic acid ratio between the xanthine content (units: μg / g) and the pyroglutamic acid content (units: μg / g) of 0.0200 or less and a pyroglutamic acid content of 40 μg / g or greater. The processed food contains at least one component (X) selected from the group consisting of a protein having had xanthine oxidase activity and a component derived from the protein.

The application provides a pyroglutamic acid transaminase mutant and application thereof, the mutant is obtained by mutation on the basis of wild-type pyroglutamic acid transaminase, and specific mutation includes at least one of the following sites: (1) the 13th isoleucine is mutated into arginine; (2) the 35th valine is mutated into arginine; (3) the 183rd asparagine is mutated into aspartic acid; and the mutant is suitable for industrial enzymatic production of L-aspartic acid and the process of amino acids taking L-aspartic acid as a precursor; especially, the I13R / V35R / N183D mutant obtained by modification has high positive catalytic activity and strict direction selectivity, and completely loses the reverse reaction activity of decomposing L-aspartic acid; the mutant is overexpressed with phosphoenolpyruvate carboxylase in L-threonine production strain THRS-6, and a high-efficiency L-threonine synthesis metabolic pathway is constructed, and the yield of L-threonine is significantly improved when glucose is used as a substrate.

The invention relates to the field of medicinal chemistry, in particular to a preparation method of L-pyroglutamic acid etogliflozin. An ethyl acetate / water system is adopted to dissolve an L-pyroglutamic acid etogliflozin crude product, after filtration, n-heptane is added, cooling and crystallization are performed to obtain the L-pyroglutamic acid etogliflozin, in the prepared product, the ratio of the etogliflozin to the L-pyroglutamic acid eutectic crystal is stable, the residual amount of a solvent is low, the content of an impurity Y can be controlled to be 0.05% or below, the minimum content can be controlled to be 0.02%, the product purity is high, and the yield is high. The yield is high. The method is low in production cost, simple to operate, high in yield, high in product purity, stable in quality and suitable for industrial production.

The application belongs to the technical field of food preparation, and particularly relates to application of pyroglutamic acid in fresh-cut fruit and vegetable preservation, browning resistance and bacterium inhibition. Fresh-cut fruit and vegetable are treated by the method, so that the browning degree of fresh-cut potato, lettuce, lotus root slice and other products during a shelf life is significantly delayed, the growth of microorganisms during the shelf life of the products is reduced, and the shelf life is prolonged. The anti-browning and bacterium-inhibiting preservative for fresh-cut fruit and vegetable provided by the application is safe, efficient and environmentally friendly.

This invention relates to the field of biochemical technology, specifically to a method for recovering glutamic acid, ammonium sulfate, and pyroglutamic acid from an isoelectric mother liquor containing glutamic acid. The method includes: crystallizing and separating ammonium sulfate and a secondary mother liquor from an isoelectric mother liquor containing no bacteria; chromatographically separating the secondary mother liquor to obtain a first eluent containing pyroglutamic acid and ammonium sulfate and a second eluent containing glutamic acid; precipitating and separating the ammonium sulfate and pyroglutamic acid in the first eluent using an organic solvent; and separating glutamic acid from the second eluent. This method can simultaneously obtain three products: glutamic acid, pyroglutamic acid, and ammonium sulfate, while ensuring high yields and purity of all three products. It offers advantages such as mild conditions, low energy consumption, and low cost, enabling industrial-scale production and possessing significant practical application value.

Disclosed are antibodies or antigen-binding fragments thereof that bind to AβpE3, an N-terminally truncated, pyroglutamic acid-modified form of amyloid beta (Aβ), and their therapeutic and diagnostic uses.

The utility model belongs to the technical field of chemical equipment, and particularly relates to a quick cooling jacket which comprises a jacket body detachably arranged on the outer side of a pipeline in a sleeving mode, a water inlet is formed in one end of the jacket body, a water outlet is formed in the other end of the jacket body, and a spiral groove is formed in the inner wall of the jacket body. The spiral groove is matched with the pipeline to form a water path communicating the water inlet and the water outlet and allowing the cooling medium to circulate. The detachable jacket is arranged on the pipeline between the filter and the crystallizing tank, and the spiral groove is formed in the inner wall of the jacket body to form the water path for communicating the water inlet with the water outlet, so that the heat exchange area is increased, and the circulation time of a cooling medium is prolonged. The temperature of the solution can be quickly and effectively reduced and the decomposition and degradation of glutamine at high temperature can be reduced especially when the crystallization solution with tonnage-level volume is treated, so that the purity and quality of glutamine are improved, the generation of impurity pyroglutamic acid is avoided, and the stability and safety of the product are ensured.

The application relates to the technical field of composite boards, and particularly discloses an anti-deformation environment-friendly composite board and a production process thereof. The composite board is made of amino-siloxane modified bamboo fibers, pyroglutamic acid-polyethylene glycol ester and poly-lactic acid which are mixed and then hot-pressed, secondarily compressed and shaped. The used materials have good degradability and reusability, meet the green environmental protection concept, have good stability and impact resistance, and can meet the demands of most users.

There is a demand for a fermented beverage that uses hops and offers a favorable, characteristic flavor typical of a fermented beverage while achieving a reduction in unsuitable grain odor.　Provided is a fermented beverage that uses hops as a raw material, has a pyroglutamic acid content of 95.0 mg / L or less, and satisfies formula (1).　Formula (1): A／B ≤ 30.0 [In formula (1), A represents the pyroglutamic acid content (unit: mg／L) and B represents the free amino nitrogen content (unit: mg / 100 mL)].

The invention discloses a method for improving the yield of glutamic acid by using an annular process formed by glutamic acid isoelectric mother liquor, and belongs to the technical field of industrial fermentation. The method comprises the following steps: carrying out membrane treatment, two-stage electrodialysis treatment, acid hydrolysis treatment, acid decoloration treatment and other technical means on the glutamic acid isoelectric mother liquor, and finally recycling the obtained hydrolysis decoloration solution to replace sulfuric acid to adjust the isoelectric crystallization operation of the fermentation liquor, thereby constructing an annular process. In the whole annular process, pyroglutamic acid in the isoelectric mother liquor is hydrolyzed into glutamic acid through acid hydrolysis, and the pyroglutamic acid and the glutamic acid in the isoelectric mother liquor are recycled and reused in the operation process of glutamic acid isoelectric crystallization, so that the yield of the glutamic acid is increased; simultaneously generated concentrated solution and concentrated water are respectively filtered by a plate frame, concentrated and dried to obtain mycoprotein and ammonium sulfate. By means of the treatment method, the yield of glutamic acid is increased, the yield of mycoprotein and the yield of ammonium sulfate are increased, and huge economic benefits and environmental benefits are achieved.

The invention discloses a metabolic marker for diagnosing lung function grading in a stable phase of chronic obstructive pulmonary disease and application of the metabolic marker. According to the invention, in a training set, the lysophosphatidylcholine (17: 0 / 0: 0) is combined with the dimethylglycine or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the 5-hydroxyindoleacetic acid or the lysophosphatidylcholine (17: 0 / 0: 0), and the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0). The combination of the L-pyroglutamic acid and the 5-hydroxyindoleacetic acid has excellent diagnosis efficiency in diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the chronic obstructive pulmonary disease in the stable phase; further, verification results in a verification set show that the four combined metabolic markers have excellent accuracy in combined diagnosis and distinguishing of patients with the lung functions of the chronic obstructive pulmonary disease at the 1-2 level and the 3-4 level in the stable phase. Therefore, the four combined metabolic markers have the prospect of being developed into a kit for diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the stable-phase chronic obstructive pulmonary disease.

The invention discloses an aqueous zinc metal battery electrolyte and a zinc metal battery, and belongs to the technical field of batteries, the aqueous zinc metal battery electrolyte comprises L-pyroglutamic acid, zinc salt and water, and the concentration of the L-pyroglutamic acid in the aqueous zinc metal battery electrolyte is 0.01-0.5 mol / L. According to the water-based zinc metal battery electrolyte disclosed by the invention, the L-pyroglutamic acid with a specific concentration is added, and after the L-pyroglutamic acid is introduced into the water-based zinc metal battery electrolyte, the L-pyroglutamic acid has the functions of reconstructing a hydrogen bond network and creating a strong acid environment; the three problems of hydrogen evolution side reaction, corrosion reaction and zinc dendrite growth at a zinc negative electrode-electrolyte interface can be solved, and the specific capacity, coulombic efficiency and cycle life of the zinc metal battery are effectively improved.

The disclosure provides a method for synthesizing free base foams of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal foams of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Provided is a beer-flavored beverage having a chromaticity of 7.5 EBC or lower, a bitterness value of 15.0 BUs or lower, and a pyroglutamic acid content of 30 mg / L or more.

The present application relates to the biomedical technology field, and particularly to a blood biomarker for early coronary heart disease diagnosis, and a screening method and application thereof.The blood biomarker comprises blood clinical indicators and plasma metabolome characteristics, the blood clinical indicators comprise direct bilirubin, aspartate aminotransferase and high-density lipoprotein, and the plasma metabolome characteristics comprise pyroglutamic acid, N-formyl-L-methionine, hypoxanthine, pinobetsin and L-valyl-alanine.The present application not only uses plasma metabolome characteristics, but also incorporates blood clinical indicators through blood routine and blood biochemical detection, compared with other methods, more comprehensively reflects the physiological and pathological state of the body, reduces the possibility of result deviation, and therefore adopts multi-dimensional blood biomarkers, which can more accurately predict the risk of early coronary heart disease.In addition, the adoption of multi-dimensional blood biomarkers can also improve the specificity and sensitivity of screening and diagnosis of early coronary heart disease.